Related Experiment Video
Updated: Jun 10, 2026
Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages
Published on: February 23, 2024
Personalized therapies in the cancer "omics" era
Alberto Ocaña1, Atanasio Pandiella
1Servicio de Oncología Médica, Complejo Hospitalario Universitario de Albacete y unidad AECC, Albacete, Spain.
Abstract:
A molecular hallmark of cancer is the presence of genetic alterations in the tumoral DNA. Understanding how these alterations translate into the malignant phenotype is critical for the adequate treatment of oncologic diseases. Several cancer genome sequencing reports have uncovered the number and identity of proteins and pathways frequently altered in cancer. In this article we discuss how integration of these genomic data with other biological and proteomic studies may help in designing anticancer therapies "a la carte". An important conclusion is that next generation treatment of neoplasias must be based on rational drug combinations that target various pathways and cellular entities that sustain the survival of cancer cells.
Insights
Cancer genetic alterations drive malignancy. Integrating genomic data with other studies aids in personalized anticancer therapies and rational drug combinations for improved neoplasia treatment.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Genetic alterations in tumoral DNA are a key characteristic of cancer.
- Understanding the link between genetic changes and the malignant phenotype is crucial for effective cancer treatment.
Purpose of the Study:
- To discuss how integrating genomic data with other biological and proteomic studies can facilitate the design of personalized anticancer therapies.
- To highlight the importance of rational drug combinations targeting multiple pathways for next-generation cancer treatment.
Main Methods:
- Review and integration of findings from cancer genome sequencing reports.
- Analysis of protein and pathway alterations frequently observed in cancer.
- Discussion of integrating genomic data with proteomic and other biological studies.
Main Results:
- Cancer genome sequencing reveals numerous protein and pathway alterations.
- Integration of diverse biological data enables a "la carte" approach to anticancer therapy design.
Conclusions:
- Next-generation cancer treatment necessitates rational drug combinations.
- Targeting multiple pathways and cellular components sustaining cancer cell survival is essential for effective neoplasia management.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...